Efficacy and safety of non-surgical short-wave radiofrequency treatment of mild-to-moderate erythematotelangiectatic rosacea: a prospective, open-label pilot study

Although various treatments have been proposed for the management of rosacea, achieving complete remission of persistent erythema remains challenging. Short-wave radiofrequency (SWRF) treatment has been shown to repair skin barriers and reduce chronic inflammation. However, limited studies have evaluated the effectiveness of SWRF treatment for erythematotelangiectatic rosacea (ETR). A prospective, open-label pilot study using SWRF therapy was conducted on 30 patients with mild-to-moderate ETR. During the first stage, the patients underwent a single, full-face treatment and were evaluated before and after the session, as well as on the 7th and 15th day post-treatment. During the second stage, ten treatment sessions were administered, and the patients were evaluated before and after the tenth session, as well as 1 month after the treatment. Adverse events were recorded during each treatment session, and the patients were followed up for 3 months after the last session. Twenty-eight patients completed the entire trial. On the 7th day after the single treatment, the global score (total score of flushing, persistent erythema, and telangiectasia) of ETR improved from 5.23 +/- 1.09 to 4.00 +/- 0.76 relative to the baseline value (p < 0.05); moreover, the overall treatment satisfaction improved from 7.27 +/- 0.89 to 4.90 +/- 0.91 (p < 0.05). 1 month after the tenth treatment session, the global score improved from 5.30 +/- 1.01 to 3.85 +/- 0.93 (p < 0.05), and the overall treatment satisfaction improved from 7.13 +/- 0.85 to 5.17 +/- 1.19 (p < 0.05). During the 3 month follow-up period, there were two cases of recurrence. Therefore, this report indicates that SWRF might be an effective auxiliary treatment for mild-to-moderate ETR.

Automated summary

Short-wave radiofrequency (SWRF) treatment may serve as an effective adjunctive therapy for mild-to-moderate erythematotelangiectatic rosacea (ETR), showing promising results in improving symptoms and patient satisfaction. This preliminary study evaluated the efficacy of SWRF treatment for ETR and demonstrated positive outcomes in a clinical trial setting.